- Home
- ACRS vs SIEB Comparison
ACRS vs SIEB Comparison
Compare ACRS & SIEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SIEB
- Stock Information
- Founded
- ACRS 2012
- SIEB 1886
- Country
- ACRS United States
- SIEB United States
- Employees
- ACRS N/A
- SIEB N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SIEB Investment Bankers/Brokers/Service
- Sector
- ACRS Health Care
- SIEB Finance
- Exchange
- ACRS Nasdaq
- SIEB Nasdaq
- Market Cap
- ACRS 127.6M
- SIEB 148.8M
- IPO Year
- ACRS 2015
- SIEB N/A
- Fundamental
- Price
- ACRS $1.26
- SIEB $4.03
- Analyst Decision
- ACRS Strong Buy
- SIEB
- Analyst Count
- ACRS 7
- SIEB 0
- Target Price
- ACRS $10.67
- SIEB N/A
- AVG Volume (30 Days)
- ACRS 801.8K
- SIEB 63.9K
- Earning Date
- ACRS 05-08-2025
- SIEB 05-20-2025
- Dividend Yield
- ACRS N/A
- SIEB N/A
- EPS Growth
- ACRS N/A
- SIEB 57.14
- EPS
- ACRS N/A
- SIEB 0.33
- Revenue
- ACRS $17,777,000.00
- SIEB $83,639,000.00
- Revenue This Year
- ACRS N/A
- SIEB N/A
- Revenue Next Year
- ACRS $425.96
- SIEB N/A
- P/E Ratio
- ACRS N/A
- SIEB $11.45
- Revenue Growth
- ACRS N/A
- SIEB 17.39
- 52 Week Low
- ACRS $0.95
- SIEB $1.41
- 52 Week High
- ACRS $5.17
- SIEB $3.85
- Technical
- Relative Strength Index (RSI)
- ACRS 43.64
- SIEB 78.40
- Support Level
- ACRS $1.20
- SIEB $3.29
- Resistance Level
- ACRS $1.46
- SIEB $3.75
- Average True Range (ATR)
- ACRS 0.11
- SIEB 0.23
- MACD
- ACRS 0.02
- SIEB 0.03
- Stochastic Oscillator
- ACRS 41.77
- SIEB 100.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.